Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)

NCT05178017 · View on ClinicalTrials.gov ↗

Study Summary

A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.

Interventions

  • DIAGNOSTIC_TEST Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program

Study Locations (1)

Florida

  • Oxford Biomedical Technologies, Inc. — Riviera Beach

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2021-09-01
Est. Completion 2026-12-31
Phase NA

Sponsor

Oxford Biomedical Technologies

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05178017

The ClinicalTrials.gov registry entry for NCT05178017 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oxford Biomedical Technologies, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with IBS - Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention — of which Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05178017 reports 1 study location spanning 1 distinct geographic area — top geographies include Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05178017 about?

NCT05178017 is a clinical study titled "Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)". A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.

What is the current status of trial NCT05178017?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2021-09-01. Estimated completion is 2026-12-31.

What conditions does trial NCT05178017 study?

This clinical trial studies the following conditions: IBS - Irritable Bowel Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05178017?

The interventions under investigation include: Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05178017?

This trial is sponsored by Oxford Biomedical Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05178017 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial